Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 18, 2018JAMA OncologyOpen Access

Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2

View Full Paper
Ask AI
Bookmark
Share

Authors

AFAmir T. FathiUniversity of Southern CaliforniaCDCourtney D. DiNardoThe University of Texas MD Anderson Cancer CenterIKIrina KlineIntegrated BioTherapeutics (United States)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Fathi et al. (2018) studied this question.

synapsesocial.com/papers/6a819e0c5feb15765cbf618chttps://doi.org/10.1001/jamaoncol.2017.4695
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome.2000 · 259 citations
  2. 2Myeloid malignancies and the microenvironment2016 · 175 citations
  3. 3Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML2012 · 180 citations
  4. 4World Medical Association Declaration of Helsinki2013 · 31,120 citations